Cadila Pharma drives meaningful innovation through an advanced research and development ecosystem that lies at the heart of the company’s mission. With sustained investments in R&D, we consistently delivered breakthrough therapies that address unmet medical needs, elevate standards of care, and have the potential to transform patient outcomes worldwide.
1700+
product registrations
180
API Drug Master Files
457
patents filed
158
patents granted globally
Our in-house R&D department is a cornerstone of its success. With 300+ highly skilled scientists and researchers, this multidisciplinary team works relentlessly to pioneer affordable and effective healthcare solutions. Their collective expertise spans drug discovery, formulation development, clinical research and process innovation.
Operating across more than 45 therapeutic areas and 12 medical specialities, including cardiovascular, gastrointestinal, anti-infective, respiratory, antidiabetic, analgesic, haematinic, and immunological segments, we blend scientific excellence with a deep sense of responsibility.
Our approach to innovation is defined by the integration of state-of-the-art science with ethical practices, ensuring that every discovery contributes not only to individual health but also to the greater good of society.
At Cadila Pharma, innovation is not just about creating new products; it is about creating sustainable value. We uphold global standards in clinical research, adhere to the most stringent regulatory benchmarks, and maintain absolute transparency in scientific conduct. We continue to redefine what is possible in pharmaceutical science, developing therapies that enable healthier, longer, and more fulfilling lives.
World First Innovations
We remain at the forefront of innovation, advancing global healthcare through first-in-the-world drug breakthroughs. At the heart of everything we do is service to mankind and the well-being of all. Through every unique formulation, we aim to treat illness, strengthen families, cities, nations, and life itself.
Active Pharmaceutical Ingredients (APIs)
We are globally recognised for our API manufacturing expertise, providing high-quality, cost-effective solutions across vital therapeutic areas, including respiratory, diabetology, gastroenterology, and pain management. Our cutting-edge Dahej facility, equipped with a Distributed Control System (DCS), supports efficient, sustainable production.
Formulation Development
Our formulation portfolio includes 850+ finished dosage products across 45 therapeutic areas and 12 specialities. Our formulation R&D team supports end-to-end development across domestic, regulated, and semi-regulated markets, while also enhancing existing formulations to deliver higher efficacy and better patient compliance.
Growing through strategic territory expansions, partnerships, and global collaborations to reach evolving markets with care and commitment through joint ventures and subsidiaries.
Developing a broad and accessible range of products through innovation, non-infringing processes, and strengthening our role as a responsible leader in the generics market.
Leading the way in manufacturing and supplying premium-quality, innovative speciality, and generic formulations, ensuring meaningful impact on patient lives.
Contact Us
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved
